Second Circuit Decision A Reminder that Alleged FDCA violations don’t always equal FCA violations
FDA Law Blog
NOVEMBER 30, 2022
According to the Realtor, these CIP qualification discrepancies “may lead to contamination” and “…over time [lead to] to adulterated [Gamunex] product and significant risk of patient harm.” 3729) quit tam suit, alleging that Grifols USA, Grifols Biologicals, Grifols, S.A.,
Let's personalize your content